DADC
SGMO

D.A. Davidson & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

D.A. Davidson & Co’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-9,600
Closed -$84K – 1839
2017
Q2 		$84K Buy
9,600
+897
+10% +$5.75K ﹤0.01% 1344
2017
Q1 		$45K Buy
8,703
+2,952
+51% +$11.8K ﹤0.01% 1561
2016
Q4 		$17K Buy
5,751
+409
+8% +$1.49K ﹤0.01% 1976
2016
Q3 		$24K Buy
5,342
+596
+13% +$3.03K ﹤0.01% 1799
2016
Q2 		$27K Buy
4,746
+1,821
+62% +$11.6K ﹤0.01% 1660
2016
Q1 		$17K Buy
2,925
+914
+45% +$5.49K ﹤0.01% 1762
2015
Q4 		$18K Buy
2,011
+430
+27% +$3.31K ﹤0.01% 1744
2015
Q3 		$8K Buy
+1,581
New +$13K ﹤0.01% 1917

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.A. Davidson & Co's SGMO Position: Q3 2017 in Review

D.A. Davidson & Co sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2017, closing a stake of 9,600 shares — an estimated $84K sold.

D.A. Davidson & Co first reported a position in SGMO in Q3 2015 and held it in 8 quarters. The position peaked at $84K in Q2 2017. 148 funds tracked by Wall St. Rank hold SGMO as of Q3 2017.

  • D.A. Davidson & Co reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 9,600 SANGAMO THERAPEUTICS INC shares in Q3 2017, an estimated $84K.
  • D.A. Davidson & Co first reported a position in SANGAMO THERAPEUTICS INC in Q3 2015 and held it in 8 quarters.
  • D.A. Davidson & Co's SANGAMO THERAPEUTICS INC position peaked at $84K in Q2 2017.
  • 148 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.